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1. INTRODUCTION {#mgg31015-sec-0005}
===============

Thyroid cancer is the most common endocrine tumor. There are more than 800,000 cases diagnosed each year in the United States, and the incidence continues to rise (Miller et al., [2016](#mgg31015-bib-0011){ref-type="ref"}). Nonmedullary thyroid cancer (NMTC) originates from follicular cells and encompasses papillary thyroid cancer (PTC), follicular thyroid cancer, and anaplastic thyroid carcinoma. NMTC accounts for approximately 90% of all thyroid cancers (Zhang & Xing, [2016](#mgg31015-bib-0020){ref-type="ref"}). Only a small subset of NMTC, mainly PTC, shows family aggregation, which accounts for 3%--9% of all thyroid cancers (Klubo‐Gwiezdzinska et al., [2017](#mgg31015-bib-0009){ref-type="ref"}).

Familial NMTC (FNMTC) is defined as a family of two or more first‐degree relatives diagnosed as having thyroid cancer derived from the thyroid follicular epithelium cell and excludes a history of exposure to radiation. FNMTC can be divided into two groups on the basis of its clinical manifestations. The first group is called syndromic FNMTC and is characterized by the familial syndrome, including familial adenomatous polyposis, Gardner\'s syndrome, Cowden\'s disease, Carney complex type 1, Werner syndrome, papillary renal neoplasia, etc. The second group, termed nonsyndromic FNMTC, is mainly characterized by NMTC (Bano & Hodgson, [2016](#mgg31015-bib-0003){ref-type="ref"}; Yu et al., [2015](#mgg31015-bib-0017){ref-type="ref"}). Recently, researchers have found that FNMTC has higher recurrence, greater invasiveness, and worse prognosis than sporadic NMTC (SNMTC). In addition, the age of FNMTC onset is earlier than SNMTC, which generally means that patients undergo more surgical procedures or other active treatments (Tavarelli et al., [2015](#mgg31015-bib-0013){ref-type="ref"}; Wang et al., [2015](#mgg31015-bib-0015){ref-type="ref"}; Zhang, Yang, Meng, Chen, & Pang, [2016](#mgg31015-bib-0019){ref-type="ref"}). At present, the genetics and pathogenesis of SNMTC are relatively clear, whereas for FNMTC, they remain ambiguous. FNMTC was first reported in 1955 by Robinson and Orr in several monozygotic twins who were diagnosed as having thyroid cancer (Robinson & Orr, [1955](#mgg31015-bib-0012){ref-type="ref"}). Current research suggests that FNMTC is an autosomal dominant genetic disease with incomplete penetrance and variable expressivity. Despite some reports, the specific pathogenic genes and mechanisms underlying FNMTC are not yet clear. Therefore, finding the pathogenic FNMTC susceptibility gene mutations would be of great significance and would enable a more in‐depth assessment of the risk of FNMTC among members of a family with the disease.

Here we report a study on a pedigree containing three PTC‐affected members. We conducted whole‐exome sequencing for these three affected family members as well as for three healthy family members. We identified gene mutation sites that were common to the affected relatives but were not found in the healthy relatives. Using Sanger sequencing, we verified the mutations in these candidate pathogenic FNMTC susceptibility genes.

1.1. Case Report {#mgg31015-sec-0006}
----------------

One kindred with FNMTC (patient II.2) was referred to our institution for further investigation of the patient\'s clinical and genetic characteristics. Patient II.2 was examined and was diagnosed as having PTC. Patient I.1 was the proband\'s father, who was diagnosed as having PTC. Two other relatives (III.1 and III.2) were also diagnosed as having PTC on the basis of ultrasonographic examinations. Other family members were negative for the presence of thyroid nodules or of thyroid cancer as assessed by ultrasonography. The family had not been exposed to radioactive materials, and they did not have a history of other primary cancers (Figure [1](#mgg31015-fig-0001){ref-type="fig"}).

![Pedigree of the family with familial non‐medullary thyroid cancer (FNMTC). Filled and unfilled symbols represent NMTC‐affected and NMTC‐unaffected individuals, respectively. Circles and squares represent females and males, respectively. The arrow indicates the proband; the slash, a deceased member. Blue circles represent family members who participated in the whole‐exome sequencing](MGG3-7-e1015-g001){#mgg31015-fig-0001}

2. METHODS {#mgg31015-sec-0007}
==========

2.1. Editorial policies and ethical considerations {#mgg31015-sec-0008}
--------------------------------------------------

This study was approved by the Ethics Committee of Anhui Medical University. The peripheral blood of the proband and his family members were obtained at the Department of Otorhinolaryngology, Head and Neck Surgery of the First Affiliated Hospital of Anhui Medical University. Each person volunteered to participate in this study and signed an informed consent form to be included in the present study.

2.2. Genetic studies {#mgg31015-sec-0009}
--------------------

Peripheral blood was collected from the proband, the two other affected relatives, and three healthy relatives. DNA was extracted from the peripheral blood using standard procedures and following manufacturer\'s instructions (Vazyme Biotech Co. Ltd). High‐throughput sequencing of DNA samples was performed after whole‐exome capture. The Exome Aggregation Consortium (ExAC) data and the Genome Aggregation Database (gnomAD) were used to filter the results obtained. The filter criteria were the allele frequency of the variant in the East Asian populations of the ExAC database (ExAC EAS) of \<0.05 and of the gnomAD database (gnomAD EAS) of \<0.05 and excluded synonymous mutations or noncoding flanking regions. The remaining genes that have been found to be closely related to tumor development were screened out. Sanger sequencing was used for final validation.

2.3. Sanger sequencing {#mgg31015-sec-0010}
----------------------

GenBank sequences of *ANO7* (accession number: NM‐001001891.3), *CAV2* (accession number: NM‐001233.5), *KANK1* (accession number: NM‐015158.3), *PIK3CB* (accession number: NM‐006219.2), *PKD1L1* (accession number: NM‐138295.4), *PTPRF* (accession number: NM‐002840.4), *RHBDD2* (accession number: NM‐001040456.2) were referred to the reference sequence database in National Center for Biotechnology Information (NCBI). Sanger sequencing was used to verify genetic susceptibility mutations. The primers are listed in Table [1](#mgg31015-tbl-0001){ref-type="table"}.

###### 

Primers of susceptibility mutations

  Gene     Forward primer (5\'→3\')   Reverse primer (5\'→3\')
  -------- -------------------------- --------------------------
  ANO7     TGCTCTGACTACGAGGACACT      ACCAAGGTGAGATGGGGGAC
  CAV2     CCGCTGTGATCCAATTATCC       CCAGACCTGGGGTCCAAGTA
  KANK1    AGCCACCATGCAGATGACAC       CAGGCGTTTCAGAGCAATGG
  PIK3CB   TTGCCTTCTTTTGACCTATCTT     TTCTGAGCCCTTTTCTTTCTT
  PTPRF    AGGAGCTTCAGGCTACTCTGT      TGGGAGTTGGGTACTCAGGA
  RHBDD2   TAGGCGGCTTATAACCTGGC       TGATGACACAGCCTCGAATG
  PKD1L1   GCGACTCACATTTTACTTCCA      CATCCCCTGTCCTTCCTT
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3. RESULTS {#mgg31015-sec-0011}
==========

3.1. Identification of pathogenic FNMTC susceptibility gene mutations {#mgg31015-sec-0012}
---------------------------------------------------------------------

We performed whole‐exome sequencing using the genomic DNA extracted from the peripheral blood from the three affected and three healthy members of a family who were diagnosed as having FNMTC to identify candidate pathogenic genes. The pedigree of the family with FNMTC is illustrated in Figure [1](#mgg31015-fig-0001){ref-type="fig"}. After we conducted bioinformatics analyses, we identified 28 rare pivotal single‐nucleotide polymorphism (SNP) mutations, and among them, 7 FNMTC susceptibility candidate genes with SNP mutations: anoctamin 7 (*ANO7*, OMIM: 605096), caveolin 2 (*CAV2*, OMIM: 601048), KN motif and ankyrin repeat domains 1 (*KANK1*, OMIM: 607704), phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit beta (*PIK3CB*, OMIM: 602925), polycystin 1 like 1, transient receptor potential channel interacting (*PKD1L1*, OMIM: 609721), protein tyrosine phosphatase receptor type *F* (*PTPRF*, OMIM: 179590), and rhomboid domain containing 2 (*RHBDD2*, OMIM: 615203) (Figure [2](#mgg31015-fig-0002){ref-type="fig"}, Tables [2](#mgg31015-tbl-0002){ref-type="table"} and [3](#mgg31015-tbl-0003){ref-type="table"}). Sanger sequencing was subsequently performed to verify the mutations in these seven candidate genes (Figure [3](#mgg31015-fig-0003){ref-type="fig"}).

![Flow chart for mutation screening. In total, 28 pivotal genes with mutations were selected from the whole‐exome sequencing. Among them, seven genes with nonsynonymous mutation sites were identified as potentially involved in tumorigenesis and development. Sanger sequencing was used for further verification of the mutations](MGG3-7-e1015-g002){#mgg31015-fig-0002}

###### 

Twenty‐eight pivotal genes with nonsynonymous mutations in the present family with FNMTC

  Gene         Cytoband   SNP annotation   ExAC ALL   ExAC EAS   gnomAD ALL   gnomAD EAS
  ------------ ---------- ---------------- ---------- ---------- ------------ ------------
  AK2          1p35.1     rs113711467      0.0097     0.0043     0.001        0
  ALDH9A1      1q24.1     rs141131078      0.0003     0.0037     ---          0.0018
  ANO7         2q37.3     rs57677160       0.2022     0.0145     0.2013       0.0185
  C5orf49      5p15.31    rs76872483       ---        0.0429     0.0035       0.0347
  C9orf129     9q22.31    rs62572859       ---        0.041      0.1587       0.0316
  CAV2         7q31.2     rs8940           0.1531     0.0079     0.1522       0.0105
  CEP162       6q14.2     rs201104500      0.0003     0.0034     0.0003       0.0043
  CYS1         2p25.1     ---              0.0013     0.0185     0.0005       0.0105
  KANK1        9p24.3     rs28374506       0.0424     0.0087     0.0909       0.0086
  KRTAP10‐12   21q22.3    rs61745911       0.0799     0.0266     0.1131       0.0309
  KRTAP10‐9    21q22.3    rs62220926       0.0835     0.0083     0.1299       0.013
  MUC4         3q29       ---              ---        0          ---          0.0016
  NUS1         6q22.1     rs28362519       0.0007     0.0095     0.0005       0.008
  PCDHA8       5q31.3     ---              0.0003     0.0032     0.0002       0.0037
  PIK3CB       3q22.3     rs375961764      ---        0.0001     ---          0
  PKD1L1       7p12.3     rs17131915       0.0058     0.0062     0.0169       0.0074
  PTPRF        1p34.2     rs17849118       0.0003     0.0049     ---          0.0012
  RHBDD2       7q11.23    rs11547498       0.0004     0.0054     0.0002       0.0031
  RHCE         1p36.11    rs143715642      0.0005     0.0074     0.0005       0.0086
  SFTPC        8p21.3     rs75902455       0.0004     0.0051     0.0004       0.0062
  SH3TC2       5q32       rs186864272      0.0001     0.0019     0.0001       0.0025
  SORBS3       8p21.3     rs3758036        0.0035     0.0475     0.0022       0.0401
  SPAG11B      8p23.1     ---              0.0002     0.0002     ---          0
  SZT2         1p34.2     rs150966402      0.0014     0.0191     .            0.0234
  TMPRSS13     11q23.3    ---              0.0001     0.0015     ---          0.0018
  TTC22        1p32.3     rs12144325       0.1191     0.0163     0.1073       0.013
  VLDLR        9p24.2     rs17848383       0.0002     0.0034     0.0001       0.0025
  ZDHHC11      5p15.33    ---              ---        0.0245     ---          0.0171

Abbreviations: EAS, East Asian population; ExAC, Exome Aggregation Consortium; FNMTC, familial non‐medullary thyroid cancer; gnomAD, Genome Aggregation Database; SNP, single‐nucleotide polymorphism.
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###### 

Seven genetic susceptibility genes identified from the 28 pivotal genes with mutations in this FNMTC family

  -------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------- ------------------------------------------------- ------------------------------------
  Gene                       ANO7                                                                                                                         CAV2                                                                   KANK1                                                                 PIK3CB                                                                          PKD1L1                     PTPRF                                             RHBDD2
  Cytoband                   2q37.3                                                                                                                       7q31.2                                                                 9p24.3                                                                3q22.3                                                                          7p12.3                     1p34.2                                            7q11.23
  Accession number           NM‐001001891.3                                                                                                               NM‐001233.5                                                            NM‐015158.3                                                           NM‐006219.2                                                                     NM‐138295.4                NM‐002840.4                                       NM‐001040456.2
  Type                       Nonsynonymous SNV                                                                                                            Nonsynonymous SNV                                                      Nonsynonymous SNV                                                     Nonsynonymous SNV                                                               Nonsynonymous SNV          Nonsynonymous SNV                                 Nonsynonymous SNV
  SNP annotation             rs57677160                                                                                                                   rs8940                                                                 rs28374506                                                            rs375961764                                                                     rs17131915                 rs17849118                                        rs11547498
  OMIM                       605,096                                                                                                                      601,048                                                                607,704                                                               602,925                                                                         609,721                    179,590                                           615,203
  ExAC ALL                   0.20                                                                                                                         0.15                                                                   0.04                                                                  ---                                                                             0.01                       0.00                                              0.00
  ExAC EAS                   0.01                                                                                                                         0.01                                                                   0.01                                                                  0.00                                                                            0.01                       0.00                                              0.01
  GnomAD ALL                 0.20                                                                                                                         0.15                                                                   0.09                                                                  ---                                                                             0.02                       ---                                               0.00
  GnomAD EAS                 0.02                                                                                                                         0.01                                                                   0.01                                                                  0.00                                                                            0.01                       0.00                                              0.00
  Tumor‐associated disease   Prostate cancer; breast cancer                                                                                               Thyroid cancer; prostate cancer; breast cancer; renal cell carcinoma   Gastric cancer; renal cell carcinoma; peripheral nerve sheath tumor   Thyroid cancer; breast cancer; glioblastoma                                     Breast cancer              Gastric cancer; prostate cancer; lung cancer      Breast cancer; colorectal cancer
  Gene Ontology annotation   Intracellular calcium activated chloride channel activity; phospholipid scramblase activity                                  Protein homodimerization activity; D1 dopamine receptor binding        Beta‐catenin binding                                                  Transferase activity; transfers phosphorus‐containing groups; kinase activity   Calcium channel activity   Phosphatase activity                              Serine‐type endopeptidase activity
  Pathway                    Ion channel transport; transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds   EGF/EGFR signaling pathway; syndecan−2‐mediated signaling events       ---                                                                   Glioma and development dopamine D2 receptor transactivation of EGFR             ---                        Transmission across chemical synapses; adhesion   ---
  -------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------- ------------------------------------------------- ------------------------------------

Abbreviations: EAS, East Asian population; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ExAC, Exome Aggregation Consortium; FNMTC, familial nonmedullary thyroid cancer; gnomAD, Genome Aggregation Database; SNP, single‐nucleotide polymorphism; SNV, single‐nucleotide variant.
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![Sequence chromatograms for PTPRF (NM‐002840.4, c.4516C\>G), PIK3CB (NM‐006219.2, c.1808C\>G), RHBDD2 (NM‐001040456.2, c.254G\>A), CAV2 (NM‐001233.5, c.388C\>G), KANK1 (NM‐015158.3, c.630C\>G), PKD1L1 (NM‐138295.4, c.2434G\>C, A), ANO7 (NM‐001001891.3, c.1481C\>T) in this family](MGG3-7-e1015-g003){#mgg31015-fig-0003}

4. DISCUSSION {#mgg31015-sec-0013}
=============

Thyroid cancer is the fifth most common cancer in women in the United States, and the incidence worldwide continues to rise (Cabanillas, McFadden, & Durante, [2016](#mgg31015-bib-0004){ref-type="ref"}). The prognosis is generally favorable for patients receiving an early diagnosis of PTC and follicular thyroid cancer. However, the risk of death increases significantly in clinical stages III and IV owing to metastasis, especially among patients with FNMTC. Therefore, understanding the mechanisms of FNMTC development and progression will likely improve the diagnosis, treatment, and prognosis of families with this disease. High‐throughput sequencing technologies can detect mutation sites in humans and have been widely used to study the molecular mechanisms of various types of cancers. In the present study, we identified 28 rare nonsynonymous SNPs and seven genes with rare nonsynonymous SNPs (*ANO7*, *CAV2*, *KANK1*, *PIK3CB*, *PKD1L1*, *PTPRF*, and *RHBDD2*) associated with cancer development in a pedigree with members diagnosed as having FNMTC. These seven genes have not previously been reported as being associated with FNMTC.

Among the seven candidate pathogenic FNMTC susceptibility genes, *PIK3CB* and *CAV2* have been reported to be involved in the development of thyroid cancer (Aldred et al., [2004](#mgg31015-bib-0002){ref-type="ref"}; Campos et al., [2014](#mgg31015-bib-0005){ref-type="ref"}; Xing, [2010](#mgg31015-bib-0016){ref-type="ref"}). *PIK3CB* encodes an isoform of the catalytic subunit of phosphoinositide 3‐kinase (PI3K). Recent studies have shown that the accumulation of genetic alterations in the PI3K/Akt pathway may increase the invasiveness of thyroid cancer, which may be one of the reasons why FNMTC is more aggressive than SNMTC. *CAV2* is a major component of the inner surface of caveolae and is involved in essential cellular functions, including signal transduction, cellular growth control, and apoptosis. Caveolins are known to play an important role in tumor initiation and progression, potentially functioning as tumor suppressors. CAV1 is expressed in thyroid cancer and other tumors, whereas less is known about CAV2. Studies have found that CAV2 promotes the growth of renal cell carcinoma through the epidermal growth factor receptor (EGFR)/PI3K/Akt signaling pathway, and the expression of CAV2 is associated with poor prognosis in invasive breast cancer (Liu, Shangli, & Hu, [2018](#mgg31015-bib-0010){ref-type="ref"}). Given the rare mutations observed in *CAV2* in the present family with FNMTC and its role in the EGFR/PI3K/Akt signaling pathway, we speculate that *CAV2* is likely to be a susceptibility gene in the pathogenesis of FNMTC. KANK1 is a member of the Kank family, which is involved in the regulation of actin polymerization and cell motility through PI3K/Akt signaling pathways (Kakinuma, Zhu, Wang, Roy, & Kiyama, [2009](#mgg31015-bib-0008){ref-type="ref"}). In view of the biological function of KANK1 and the accumulation of genetic alterations in the PI3K/Akt signaling pathway, we speculate that KANK1 may also play an important role in FNMTC.

*PKD1L1* encodes a member of the polycystin protein family. Polycystin‐1 and polycystin‐2 are the products of *PKD1* and *PKD2*, genes that are mutated in most cases of autosomal dominant polycystic kidney disease (Yuasa et al., [2002](#mgg31015-bib-0018){ref-type="ref"}). However, after additional inquiry into the medical history of the present family and after auxiliary clinical examination, no member of this family had experienced or had received a diagnosis of polycystic kidney disease.

Although the functions of *ANO7*, *PTPRF*, and *RHBDD2* in thyroid cancer are still unclear, all three have been found to participate in and promote tumor development. ANO7 is a member of anoctamin family (Kaikkonen et al., [2018](#mgg31015-bib-0007){ref-type="ref"}). The anoctamin family functions as ion channels and phospholipid scramblases. Although the role of ANO7 in thyroid cancer is unclear, ANO5 has been reported to be downregulated in thyroid cancer and may promote thyroid cancer cell migration and invasion by affecting the Janus kinase--signal transducer and activator of transcription (JAK/STAT3) signaling pathway (Chang et al., [2017](#mgg31015-bib-0006){ref-type="ref"}). PTPRF is a member of the protein tyrosine phosphatase family. As a signaling molecule, members of this protein family can regulate a variety of cellular processes, such as cell growth, differentiation, mitotic cycle, and oncogenic transformation (Tian, Yang, Yang, Sun, & Liu, [2018](#mgg31015-bib-0014){ref-type="ref"}). Mutations in *PTPRF* may affect cellular signal transduction, leading to a series of physiological and pathological changes. RHBDD2 is a member of the rhomboid family. RHBDD2 overexpression has been suggested to play a role in breast cancer tumor progression, facilitating the development of more aggressive phenotypes in at least a subset of breast carcinomas (Abba et al., [2009](#mgg31015-bib-0001){ref-type="ref"}).

Among the seven genes analyzed in the present study, *PIK3CB*, *CAV2*, and *KANK1* may be involved in the development of FNMTC through the PI3K/Akt signaling pathway, possibly by increasing the invasiveness of thyroid cancer cells. Thus, we speculate that the PI3K/Akt signaling pathway is likely to play an important role in the development of FNMTC and is likely to be related to the invasiveness of FNMTC.

5. CONCLUSION {#mgg31015-sec-0014}
=============

In summary, our study identified 28 pivotal genes and seven pathogenic genes (*ANO7*, *CAV2*, *KANK1*, *PIK3CB*, *PKD1L1*, *PTPRF*, and *RHBDD2*) in a family with FNMTC. The PI3K/Akt signaling pathway may be closely related to the development of FNMTC in this family. These genes may help to diagnose FNMTC, elucidate its pathogenesis, and assess the degree of genetic risk among the various family members. However, owing to the limited sample size of the present study, the prevalence of alterations in these genes in FNMTC remains uncertain and requires future study with a large number of families.
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